Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 89M | 14.2% |
| Gross Profit | 33M | 40.9% |
| Cost of Revenue | 56M | 2.8% |
| Operating expense | 103M | 0.9% |
| Net Income | -14M | 42.2% |
| EBITDA | -6.8M | 63.4% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 668M | 1.1% |
| Total Liabilities | 436M | 1% |
| Total Equity | 232M | 1.3% |
| Shares Outstanding | 48M | 0.8% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 4M | 204.8% |
| Cash from investing | -18M | 75.2% |
| Cash from financing | 3.9M | 47% |
EPS
Financial Highlights for Mirum Pharmaceuticals in Q3 '24
Mirum Pharmaceuticals reported a revenue of 89M, which is a 14.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 33M, marking a 40.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 56M, a 2.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 103M, showing a 0.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -14M, showing a 42.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -6.8M, showing a 63.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Mirum Pharmaceuticals with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
